James R Hilaire
Overview
Explore the profile of James R Hilaire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herskovitz J, Hasan M, Machhi J, Mukadam I, Ottemann B, Hilaire J, et al.
Nanotheranostics
. 2021 May;
5(4):417-430.
PMID: 33972918
Delivery of long-acting nanoformulated antiretroviral drugs (ARVs) to human immunodeficiency virus type one cell and tissue reservoirs underlies next generation antiretroviral therapeutics. Nanotheranostics, comprised of trackable nanoparticle adjuncts, can facilitate...
2.
Kulkarni T, Bade A, Sillman B, Shetty B, Wojtkiewicz M, Gautam N, et al.
Nat Mater
. 2020 Apr;
19(8):910-920.
PMID: 32341511
Long-acting cabotegravir (CAB) extends antiretroviral drug administration from daily to monthly. However, dosing volumes, injection site reactions and health-care oversight are obstacles towards a broad usage. The creation of poloxamer-coated...
3.
Kevadiya B, Ottemann B, Mukadam I, Castellanos L, Sikora K, Hilaire J, et al.
Theranostics
. 2020 Jan;
10(2):630-656.
PMID: 31903142
Human immunodeficiency virus theranostics facilitates the development of long acting (LA) antiretroviral drugs (ARVs) by defining drug-particle cell depots. Optimal drug formulations are made possible based on precise particle composition,...
4.
Hilaire J, Bade A, Sillman B, Gautam N, Herskovitz J, Shetty B, et al.
J Control Release
. 2019 Sep;
311-312:201-211.
PMID: 31491432
Antiretroviral therapy requires lifelong daily dosing to attain viral suppression, restore immune function, and improve quality of life. As a treatment alternative, long-acting (LA) antiretrovirals can sustain therapeutic drug concentrations...
5.
Dash P, Kaminski R, Bella R, Su H, Mathews S, Ahooyi T, et al.
Nat Commun
. 2019 Jul;
10(1):2753.
PMID: 31266936
Elimination of HIV-1 requires clearance and removal of integrated proviral DNA from infected cells and tissues. Here, sequential long-acting slow-effective release antiviral therapy (LASER ART) and CRISPR-Cas9 demonstrate viral clearance...
6.
Ottemann B, Helmink A, Zhang W, Mukadam I, Woldstad C, Hilaire J, et al.
Biomaterials
. 2018 Sep;
185:174-193.
PMID: 30245386
Antiretroviral therapy (ART) has changed the outcome of human immunodeficiency virus type one (HIV-1) infection from certain death to a life free of disease co-morbidities. However, infected people must remain...
7.
Puligujja P, Balkundi S, Kendrick L, Baldridge H, Hilaire J, Bade A, et al.
Biomaterials
. 2014 Dec;
41:141-50.
PMID: 25522973
Long-acting nanoformulated antiretroviral therapy (nanoART) that targets monocyte-macrophages could improve the drug's half-life and protein-binding capacities while facilitating cell and tissue depots. To this end, ART nanoparticles that target the...